A Phase 3 interventional study of Efanesoctocog alfa in Hemophilia A, Severe, sponsored by Swedish Orphan Biovitrum. Completed at 30 sites in 14 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by Swedish Orphan Biovitrum · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing efanesoctocog alfa in Hemophilia A — 1 open to participants now, 5 under way, 2 of them phase 3. efanesoctocog alfa · Hemophilia A.
Among the 11 studies testing efanesoctocog alfa in Hemophilia A, this one is the 4th largest by enrollment, is the only one that started in 2023, is one of 5 in phase 3, and was the 6th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →1 of the 11 studies testing efanesoctocog alfa in Hemophilia A is open now, in 5 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Australia, Canada and 2 more countries
Ages 12+
By country, each count listing its studies:
efanesoctocog alfa: first FDA approval 2023 (ALTUVIIIO), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 1 · Phase 3 5 · Phase 4 3
First in 2017; this study’s year is marked. 1 started in 2023.
This study's enrollment of 93 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 74 across the 11 interventional studies. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 3 most frequent:
Swedish Orphan Biovitrum is the lead sponsor of 82 studies on the registry; 6 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
15 studies in Hemophilia A by Swedish Orphan Biovitrum: none open now, 3 under way, 1 of them phase 3. Of 12 finished, 2 (17%) have results posted.
Among the 15 studies in Hemophilia A by Swedish Orphan Biovitrum, this one is one of 2 that started in 2023, is one of 2 in phase 3, and was the 10th registered.
Swedish Orphan Biovitrum’s Hemophilia A studies by the year they started, since 2014.
4 of the studies testing efanesoctocog alfa in Hemophilia A that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04644575Phase 3Bioverativ, a Sanofi companyLong-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A | 2027-01-15 |
| NCT06716814Phase 3Swedish Orphan BiovitrumStudy to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa | 2027-03 |
| NCT06752850Swedish Orphan BiovitrumA Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis | 2026-11-17 |
| NCT06941870SanofiEfanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy | 2027-10-25 |
Add all 4 to your calendar (.ics) → With an account.
Among the 11 studies testing efanesoctocog alfa in Hemophilia A, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Swedish Orphan Biovitrum’s 15 in Hemophilia A:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
FREEDOM is a multicentre, open-label, single-arm, phase 3b study in Europe that aims to enrol approximately 90 previously treated severe haemophilia A patients aged ≥12 years, currently on prophylaxis. After a run-in period of 30-45 days, patients will receive efanesoctocog alfa prophylaxis, 50 IU/kg once-weekly for 24 months (additional preventive dose not permitted). An activity tracker and an electronic patient diary will be used to collect data on physical activity, bleeds, factor dosing, pain, and injuries from screening throughout the study.
The primary objective is to describe changes in physical activities over 24 months on efanesoctocog alfa prophylaxis, with a primary endpoint of change from baseline in International Physical Activity Questionnaire (IPAQ) at month 24.
Secondary objectives include relationship between physical activity and other variables (bleeds, joint status, pain, injuries, and quality of life); changes in joint status as assessed by HEAD-US, HJHS and MRI; occurrence of bleeds, injuries, pain. Safety and tolerability of efanesoctocog alfa will also be evaluated.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients will be treated intravenously once weekly with 50 IU/kg efanesoctocog alfa
Drug: Efanesoctocog alfa
Recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)
Also known as: BIVV001
Change from baseline in International Physical Activity Questionnaire (IPAQ) scoring
The IPAQ is a validated, 7-day recall questionnaire measuring current levels of physical activity. Scoring of the IPAQ results in a continuous variable in the form of total MET-minutes per week. Higher scores means higher physical activity level.
Time frame: Baseline and month 24
Change from baseline in International Physical Activity Questionnaire (IPAQ) scoring
The IPAQ is a validated, 7-day recall questionnaire measuring current levels of physical activity. Scoring of the IPAQ results in a continuous variable in the form of total MET-minutes per week. Higher scores means higher physical activity level.
Time frame: Baseline and month 12
International Physical Activity Questionnaire (IPAQ) score
The IPAQ is a validated, 7-day recall questionnaire measuring current levels of physical activity. Scoring of the IPAQ results in a continuous variable in the form of total MET-minutes per week. Higher scores means higher physical activity level.
Time frame: Baseline, month 6, 12, 18 and 24
Change in mean daily minutes in physical activity
Tracker-recorded
Time frame: Run-in month, month 12 and 24
Mean daily minutes of physical activity
Tracker-recorded
Time frame: Per 6-month period
Change in type of workouts
Patient and tracker reported
Time frame: Run-in month, month 12 and 24
Change in frequency of workouts
Patient and tracker reported
Time frame: Run-in month, month 12 and 24
Change in duration of workouts
Patient and tracker reported
Time frame: Run-in month, month 12 and 24
Change in patient reported intensity of workouts
The patient will report workouts in a patient diary and rate the intensity on a 5 level scale. The levels are: 1 = easy, 2 = moderate, 3 = slightly challenging, 4 = exhausting, 5 = very exhausting. The changes will be calculated on a intra-patient basis
Time frame: Run-in month, month 12 and 24
Change in tracker recorded intensity of workouts
The patient will be provided with an activity tracker that will automatically record workouts when the patient is wearing the tracker. The intensity levels will be based on the heart rate and will be presented on a 4 level scale. The levels are: 1 = out of range, 2 = fat burn, 3 = cardio, 4 = peak
Time frame: Run-in month, month 12 and 24
Mean value of patient and tracker reported type of workouts
Type of workout will be transcribed into a risk level of participating in a given activity for a haemophilia patient. Risk levels are based on a rating of 1-3 where level 1 represents a low risk of causing a bleeding episode and level 3 represents a high risk. The mean value will be calculated per 6-month period
Time frame: Per 6-month period
Mean value of frequency of workouts
Patient and tracker reported
Time frame: Per 6-month period
Mean value of duration of workouts
Patient and tracker reported
Time frame: Per 6-month period
Mean value of patient reported intensity of workouts
The patient will report workouts in a patient diary and rate the intensity on a 5 level scale. The levels are: 1 = easy, 2 = moderate, 3 = slightly challenging, 4 = exhausting, 5 = very exhausting. The mean value will be calculated per 6-month period
Time frame: Per 6-month period
Mean value of tracker recorded intensity of workouts
The patient will be provided with an activity tracker that will automatically record workouts when the patient is wearing the tracker. The intensity levels will be based on the heart rate and will be presented on a 4 level scale. The levels are: 1 = out of range, 2 = fat burn, 3 = cardio, 4 = peak The mean value will be calculated per 6-month period
Time frame: Per 6-month period
Change in mean daily number of steps
Tracker-recorded
Time frame: Run-in month, month 12 and 24
Mean daily number of steps
Tracker-recorded
Time frame: Per 6-month period
Achieving WHO-recommended levels of MVPA
Tracker-recorded
Time frame: Run-in month, month 12 and 24
Occurrence of bleeds in relation to workouts
Time frame: Baseline to month 24
Occurrence of pain in relation to workouts
Time frame: Baseline to month 24
Occurrence of injuries in relation to workouts
Time frame: Baseline to month 24
Occurrence of bleeding episodes impacting daily activity
Time frame: Baseline to month 24
Change from baseline in Haemophilia Joint Health Score (HJHS) score
The six index joints (elbows, knees and ankles) will be examined and scored. The minimum score per joint is 0, the maximum score is 20. In addition, Gait is scored on a scale from 0 to 4 based on the number of skills that are not within the normal limits. The total score will be the sum of scores across all six joints plus the gait score (range from 0 to 124, with 0 being normal and 124 being the most severe disease).
Time frame: Baseline, month 6, 12, 18, 24
Change from baseline in Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US)
The HEAD-US joint score will be calculated for six joints, the right and left ankle, knee, and elbow joints. The specific joint score is made up of three item scores, disease activity (synovitis), disease damage of articular surfaces, and disease damage of subchondral bone. Specific joint score is the sum of the three item scores for each specific joint. Its values range from 0 (minimum) to 8 (maximum).The total score represents the sum of item scores for abnormalities detected.
Time frame: Baseline, month 12 and 24
Change from baseline in haemophilic arthropathy assessed by the International Prophylaxis Study Group (IPSG) Magnetic Resonance Imaging (MRI) scale
The IPSG scale is made up of two subscores, one for soft-tissue changes and one for osteochondral changes. MRI joint score is the sum of the soft tissue and osteochondral subscores for each joint, ranging from 0-17 where 0 is absence of damage. MRI total score is the sum of joint scores across all joints.
Time frame: Baseline, month 24
Target joint development (three or more spontaneous bleeds into a single joint within a consecutive 6-month period)
The number and proportion of patients with target joint development and the total number of target joint developed will be assessed.
Time frame: Month 6, 12, 18, 24
Target joint resolution ( ≤2 bleeds into the joint within a consecutive 12-month period the joint is no longer considered a target joint)
The number and proportion of patients with target joint resolution and the total number of target joint resolutions will be assessed
Time frame: Month 6, 12, 18, 24
Target joint recurrence (≥3 spontaneous bleeds in a single joint within any consecutive 6-month period after target joint resolution)
The number and proportion of patients with target joint recurrence and the total number of target joint recurrence will be assessed
Time frame: Month 6, 12, 18, 24
Number of bleeding episodes
Time frame: Per 6-month period and cumulative
Annualized bleeding rate (ABR)
Time frame: Baseline to month 24
Total annualized efanesoctocog alfa consumption
Time frame: Baseline to month 24
Number of injections and dose to treat a bleeding episode
Time frame: Baseline to month 24
Pain reported via electronic patient diary
The patient will report pain (cause of pain, location and intensity. The intensity will reported as mild, moderately low, moderately high, severe and worst possible.
Time frame: Baseline to month 24
Pain intensity reported in the Patient-Reported Outcomes Measurement Information System (PROMIS) Scale - Pain Intensity 3a
The PROMIS Pain Intensity instrument assesses pain intensity on a 5-point Likert scale, ranging from 1 (had no pain) to 5 (very severe)
Time frame: Baseline, month 6, 12, 18, 24
Pain interference reported in the Patient-Reported Outcomes Measurement Information System (PROMIS) scale - Pain interference 6a
The PROMIS Pain Interference 6a is a patient-assessed instrument and is to measure pain interference on a 5-point Likert scale, ranging from 1 (not at all) to 5 (very much)
Time frame: Baseline, month 6, 12, 18, 24
Quality of life assessed by EuroQoL 5-dimension 5-level (EQ-5D-5L)
EQ-5D-5L assess 5 dimensions of health outcome (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each of the dimensions in the EQ-5D-5L questionnaire is divided into 5 levels: * Level 1: indicating no problem * Level 2: indicating slight problems * Level 3: indicating moderate problems * Level 4: indicating severe problems * Level 5: indicating unable to/extreme problems Patients will select a level for each dimension that best describes their health status for that dimension. A 5 digit code will be obtained, made up of the response for each dimension. This code will then be converted to an index score.The EQ-5D-5L VAS is an overall assessment of health on a scale from 1-100 that the patient provides at the end of the EQ-5D-5L questionnaire. 100 represents the best health you can imagine and 0 represents the worst health you can imagine.
Time frame: Baseline, month 6, 12, 18, 24
Assessment of treatment preference
This will be assessed with the Treatment Preference Survey that consists of 2 questions on perceived impact of treatment.
Time frame: 24 months
The occurrence of adverse events and serious adverse events
Time frame: From screening to month 24
The occurrence of clinically significant changes
Assessed by physical examination, vital signs and laboratory tests
Time frame: Baseline, month 6, 12, 18, 24
Development of inhibitors (neutralizing antibodies directed against FVIII)
Determined via the Nijmegen modified Bethesda assay
Time frame: Baseline, month 6, 12, 18, 24
The occurrence of thrombotic and embolic events
Time frame: From screening to month 24
Number of non-study medical care encounters
The number and proportion of patients having non-study medical care encounter visits will be described, as well as the corresponding total number of visits.
Time frame: From baseline to month 24
Duration of non-study medical care encounters
The duration of non-study medical care encounter visits will be described.
Time frame: From baseline to month 24
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sobi's data sharing criteria and process for requesting access can be found at: https://www.sobi.com/en/policies
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Data sharing details ↗ · www.sobi.com
No publications or documents are linked to this record.
Ran from Jul 2023 to primary completion in Jun 2026, 34 months.
Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 34 months is close to that.
Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Efanesoctocog alfa